PAT

Hamilton Offers In-Depth Exploration of DSP Operation Units and CPPs with New White Paper

Retrieved on: 
Thursday, June 15, 2023
GMP, Virus inactivation, IEX, Filtration, CQA, Chromatography, PAT, Safety, Environment, DSP, Fine chemical

BONADUZ, Switzerland, June 15, 2023 /PRNewswire/ -- Hamilton has just released a comprehensive new white paper, "Biopharma PAT: Downstream Critical Process Parameters."

Key Points: 
  • BONADUZ, Switzerland, June 15, 2023 /PRNewswire/ -- Hamilton has just released a comprehensive new white paper, "Biopharma PAT: Downstream Critical Process Parameters."
  • This whitepaper serves as a powerful resource for biopharma manufacturers seeking to design efficient and robust DSP processes and ensure product quality, safety, and efficacy in biopharmaceutical production.
  • The document is compelling for downstream skid-builders as well with multiple real-life examples provided.
  • In this white paper, Hamilton explores the CPPs which are mandatory to control for each unit operation of the DSP skid train, such as: buffer preparation/dilution, protein A and IEX chromatography, filtration, and virus inactivation.

The Digital Biomanufacturing Market is anticipated to grow at an annualized rate of 18% till 2035, claims Roots Analysis

Retrieved on: 
Tuesday, May 30, 2023
DAS, PAT, Digital, Partnership, Table, ERP, Antibody, Software, Online shopping, Renewable energy, Publishing, Video game, Retail

LONDON, May 30, 2023 /PRNewswire/ -- Roots Analysis has announced the addition of "Digital Biomanufacturing Market, 2023-2035" report to its list of offerings.

Key Points: 
  • The digital biomanufacturing market in Asia-Pacific is projected to grow at a CAGR of 20%, till 2035.
  • In addition, the digital biomanufacturing market for cell and gene therapies is anticipated to grow at a faster pace (CAGR of 20%), during 2023-2035.
  • To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/digital-biomanufacturing-market/re...
    What is the global market size of digital biomanufacturing?
  • What is the growth rate (CAGR) in the global digital biomanufacturing market?

The Digital Biomanufacturing Market is anticipated to grow at an annualized rate of 18% till 2035, claims Roots Analysis

Retrieved on: 
Tuesday, May 30, 2023
DAS, PAT, Digital, Partnership, Table, ERP, Antibody, Software, Online shopping, Renewable energy, Publishing, Video game, Retail

LONDON, May 30, 2023 /PRNewswire/ -- Roots Analysis has announced the addition of "Digital Biomanufacturing Market, 2023-2035" report to its list of offerings.

Key Points: 
  • The digital biomanufacturing market in Asia-Pacific is projected to grow at a CAGR of 20%, till 2035.
  • In addition, the digital biomanufacturing market for cell and gene therapies is anticipated to grow at a faster pace (CAGR of 20%), during 2023-2035.
  • To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/digital-biomanufacturing-market/re...
    What is the global market size of digital biomanufacturing?
  • What is the growth rate (CAGR) in the global digital biomanufacturing market?

Tata Elxsi delivers strong performance for FY23 with full year revenue growing by 27.3% and Profit after Tax growing by 37.4%

Retrieved on: 
Thursday, May 18, 2023
BSE, Tata Group, Medical device, Quarter, IDV, Health care, Communication, Annual, Annual general meeting, SIS, Transport, NSE, Media (communication), Engineering, PBT, Yoy, Growth, PAT, EPD, Bookkeeping, Retail

BANGALORE, India, May 18, 2023 /PRNewswire/ -- Tata Elxsi (BSE: 500408) (NSE: TATAELXSI), amongst the world's leading providers of design led technology services, announced its fourth quarter results for the period ending 31st March 2023.

Key Points: 
  • 3,144.7 Cr of revenue from operations for the financial year 2022-23, ending 31st March 2023, a growth of 27.3% YoY.
  • 837.9 Cr of revenue, a growth of 22.9% over the same quarter of the previous year (YoY).
  • Segment Highlights for the Quarter Ended March 31, 2023:
    Industrial Design & Visualization recorded a strong growth of 52.8% YoY in constant currency terms.
  • Our employee-friendly policies have ensured that our attrition numbers are one of the lowest amongst our peers and industry at large.

STL supports UK and Europe's digital ambitions with orders worth ~GBP 250 Mn in FY23

Retrieved on: 
Wednesday, May 17, 2023
Partnership, STL, EBITDA, Data, Vendor-neutral data centre, Growth, ARP, PAT, GBP, 3D printing

In UK and Europe, the company ably supported the region's broadband ambitions and closed the financial year with orders valued at  ~GBP 250 Mn.

Key Points: 
  • In UK and Europe, the company ably supported the region's broadband ambitions and closed the financial year with orders valued at  ~GBP 250 Mn.
  • Last year, STL strengthened its relationship with its long-standing customers in the UK and also partnered with 20 new customers across Portugal, Switzerland, Croatia, Greece, Poland, Slovenia and Norway.
  • One large-scale deal is with a new age broadband provider to provide integrated network deployment services in the UK.
  • Behind this achievement is STL's R&D and application engineering expertise which enables STL to design solutions suited for the region.

STL accelerates America's broadband rollouts through strong partnerships

Retrieved on: 
Wednesday, May 17, 2023
Growth, PAT, STL, EBITDA, USD, Cable television, 3D printing

In the US, the company ably supported the region's broadband ambitions and closed the financial year with deep engagements with top service providers.

Key Points: 
  • In the US, the company ably supported the region's broadband ambitions and closed the financial year with deep engagements with top service providers.
  • Last fiscal, the company set out to build a manufacturing base in the US and started commercial operations in its greenfield optical fiber cable facility in South Carolina.
  • This facility produces high-end, specialty optical solutions like light-weight, crush-resistant, high fiber density and compact cables, using the highest sustainability standards.
  • STL, with its local manufacturing and talent, along with its global footprint across 4 continents and 100 countries is very well positioned to meet the needs of the market.

MPS announces Q4 and FY23 results; Revenue crosses INR 500 crores, and PAT up by 25% YoY at INR 109 crores

Retrieved on: 
Tuesday, May 16, 2023
Learning, BSE, Total revenue, Education, Health, ALL, Science and technology in Asia, Peer review, HighWire, Business, King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Marketing communications, Research, MPS, CSR, USD, INR, NGO, Acquisition, FX, PBT, The Post-Pandemic World Order, Growth, GTM, Unilog Content Solutions, PAT, Scholarly method, Yoy, Platform, Mental health, EI, Television, Pharmaceutical industry, Asset management, Nursing, Life, CS, Q4

CHENNAI, Tamil Nadu, May 16, 2023 /PRNewswire-PRWeb/ -- MPS Limited (BSE: 532440; NSE: MPS LTD), a premium B2B learning and platform solutions company that powers the education, research, and corporate markets is announcing consolidated financial results for Q4 and FY23. The results were taken on record at the meeting of the Board of Directors held on May 16, 2023.

Key Points: 
  • The business surpassed its publicly stated goal of INR 100 crores in PAT and ended much ahead at INR 109 crores in FY23.
  • Q4 FY'23 revenues were up 16.5% YoY on Reported terms and 15.7% YoY on FX Adjusted terms.
  • Speaking on the performance, Rahul Arora, Chairman and CEO at MPS Limited, said, "MPS achieved a new milestone with FX-Adjusted Revenues at INR 500 crores in FY23.
  • We also surpassed our publicly stated goal of INR 100 crores in PAT and ended much ahead at INR 109 crores in FY23.

Redington announces FY23 Results: 27% Revenue and 20% Operating profit growth, highest ever

Retrieved on: 
Tuesday, May 16, 2023
Cloud, Center of excellence, Internet of things, Redington, SMB, Security, NSE, Internet, Investment, Generative, Yoy, Growth, PAT, R, Cloud Security Alliance

21,895 Crores, overall global revenues for Q4 have been the highest ever for any quarter growing by a strong 26% YoY and at Rs.

Key Points: 
  • 21,895 Crores, overall global revenues for Q4 have been the highest ever for any quarter growing by a strong 26% YoY and at Rs.
  • 590 Crores, it has registered highest ever Q4 operating profit with a 15% YoY.
  • For the full year FY23 the firm reported a revenue of Rs.
  • The business involves various risks, and uncertainties that could result in the actual results to differ materially from those indicated here.

Redington announces FY23 Results: 27% Revenue and 20% Operating profit growth, highest ever

Retrieved on: 
Tuesday, May 16, 2023
Cloud, Center of excellence, Internet of things, Redington, SMB, Security, NSE, Internet, Investment, Generative, Yoy, Growth, PAT, R, Cloud Security Alliance

21,895 Crores, overall global revenues for Q4 have been the highest ever for any quarter growing by a strong 26% YoY and at Rs.

Key Points: 
  • 21,895 Crores, overall global revenues for Q4 have been the highest ever for any quarter growing by a strong 26% YoY and at Rs.
  • 590 Crores, it has registered highest ever Q4 operating profit with a 15% YoY.
  • For the full year FY23 the firm reported a revenue of Rs.
  • The business involves various risks, and uncertainties that could result in the actual results to differ materially from those indicated here.

EQS-News: leon-nanodrugs GmbH: LEON appoints Dr. Setu Kasera as Chief Scientific Officer

Retrieved on: 
Tuesday, May 16, 2023
GMP, LEON, Drug development, University, Engineering, CSO, Head, CMC, Master of Philosophy, Research, Nanou (film), Doctor of Philosophy, Seto dialect, Gesellschaft mit beschränkter Haftung, Chemistry, Nanom, PAT, R, LNP, API, Nanotechnology, Stieneke van der Graaf, Medical device, Fine chemical, Science

leon-nanodrugs GmbH (LEON) is a leading developer of innovative nano-encapsulation devices, seamlessly scalable from R&D to GMP market supply

Key Points: 
  • leon-nanodrugs GmbH (LEON) is a leading developer of innovative nano-encapsulation devices, seamlessly scalable from R&D to GMP market supply
    May 16, 2023 – Munich (Germany) – leon-nanodrugs GmbH (“LEON”), a disrupting enabler of nanotechnology for the pharmaceutical industry, today announced the appointment of Dr. Setu Kasera as Chief Scientific Officer, effective May 15, 2023.
  • Dr. Setu Kasera succeeds Dr. Frank Stieneker, who developed the core of LEON’s innovative reactor technology for its GMP-tailored devices.
  • As CSO, Setu will continue the development of LEON’s devices to completion and tailor the product offering to LEON’s target groups.
  • Dr. Setu Kasera received her MPhil and her PhD in chemistry from the University of Cambridge, UK, for her research in nanotechnology.